Fujirebio develops in vitro diagnostic biomarker technologies, testing solutions, and contract development and manufacturing services, carrying innovations from research through clinical validation and commercialization. Its work spans diagnostic content and platforms, with a notable focus on blood-based neurological testing, including Alzheimer’s disease biomarkers. The H.U. Group company supports partners through clinical and regulatory services and maintains a biospecimen bank of more than 50,000 samples.
Good Clinical Practice (GCP)
Compliance program
CE Marked
Registration
IVDR
Compliance program
CE
Quality certification